Tek antagonists comprising soluble tek extracellular binding domain
US6413932B1 · kind B1 · utility
54Cited by
4References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2000 |
| Grant date | Jul 2, 2002 |
| Priority date | — |
| Expiry date | Jun 7, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.